reports
Bioasis Provides Corporate Update and Announces Suspension of Operatio...
Bioasis Provides Corporate Update and Announces Suspension of Operations NEW HAVEN, Conn., June 20, 2023 (GLOBE NEWSWIRE) -- . (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today provided an update on its financial condition and operations...
Bioasis Provides Update on Business Operations
Bioasis Provides Update on Business Operations NEW HAVEN, Conn., March 23, 2023 (GLOBE NEWSWIRE) -- (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need provides this update on its business operations. On February 28, 2023, Lind Global Macro Fun...
Bioasis Announces AGM Results and Provides Update on Financial Positio...
Bioasis Announces AGM Results and Provides Update on Financial Position NEW HAVEN, Conn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- . (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, is pleased to announce that all resolutions were passed by the requ...
Bioasis Technologies Inc. Announces Termination of Arrangement Agreeme...
Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- . (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced that it has terminated th...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022 NEW HAVEN, Conn., Jan. 19, 2023 (GLOBE NEWSWIRE) -- . (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced that it has...
Bioasis Technologies Inc. Mails Management Information Circular for An...
Bioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of Securityholders NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- . (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced that it h...
Bioasis Technologies Inc. Announces Amendments to Arrangement Agreemen...
Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc NEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) -- . (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced the following amendments ...
Bioasis Technologies Inc. Announces Shareholder Webinar
Bioasis Technologies Inc. Announces Shareholder Webinar NEW HAVEN, Conn., Dec. 14, 2022 (GLOBE NEWSWIRE) -- . (TSXV:BTI) (OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today is pleased to announce that it will be holding an investor call on Tuesday,...
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc US$10M Registered Direct Offering and PIPE to Strengthen Balance Sheet of Combined Company NEW HAVEN, Conn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- . (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of hig...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022 NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) -- . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced it has file...
Bioasis Technologies Inc. Announces Stock Option Grants
Bioasis Technologies Inc. Announces Stock Option Grants NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced that it has granted stock options to acquire a total of 2,011,000 co...
Bioasis Announces Filing of Its First Quarter Financial Statements and...
Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A NEW HAVEN, Conn., July 29, 2022 (GLOBE NEWSWIRE) -- (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced today that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended May 31, 2022. All are available under the Company’s profile on and on the Company’s website at . On behalf of th...
Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets
Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets Phase 2 ready assets transform Bioasis into a clinical stage company with a multi-asset pipeline focused on rare and orphan drug indications Unique approach to neurodegeneration targeting remyelination Initial indications Chronic Inflammatory Degenerative Polyneuropathy, Guillain-Barre Syndrome, and Multiple Sclerosis related Optic Neuritis Complements Bioasis’ differentiated xB3TM platform for delivering therapeutics across the blood-brain barrier NEW HAVEN, Conn., U.S.A., June 16, 2022 (GLOBE NEWSWIRE) -- (TSXV:BTI.V; OTCQB:BIOA...
Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Fin...
Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A NEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has filed its audited annual financial statements and managem...
Bioasis and Neuramedy Enter into Research Collaboration and License Ag...
Bioasis and Neuramedy Enter into Research Collaboration and License Agreement NEW HAVEN, CONN., U.S.A., May 10, 2022 (GLOBE NEWSWIRE) -- . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”) a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced today that it has entered into a research collaboration and license agreement with Neuramedy Co Ltd (“Neuramedy”) of Seoul, Korea. Neuramedy is a biotech company researching and developing innovative solutions for neurodegenerative d...
Bioasis Enters Into Research Collaboration With Janssen
Bioasis Enters Into Research Collaboration With Janssen NEW HAVEN, CONN., U.S.A., April 11, 2022 (GLOBE NEWSWIRE) -- . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”), a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”), announced today that it has entered into a research collaboration with Janssen Biotech, Inc., one of the Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement, Janssen will have the option to research, develop and commercialize novel pr...
Bioasis to Attend and Present at Upcoming Industry Conference
Bioasis to Attend and Present at Upcoming Industry Conference NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that Dr. Deborah Rathjen, Executive Chair and Chief Executive Officer of Bioasis will attend and pre...
Bioasis Announces $200,000 Non-Brokered Private Placement
Bioasis Announces $200,000 Non-Brokered Private Placement NEW HAVEN, Conn., Feb. 17, 2022 (GLOBE NEWSWIRE) -- . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has completed a non-brokered private placement of 770,000 common shares to an arm’s length investor at...
Bioasis Announces Filing of Its Quarter and Financial Statements and M...
Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021 NEW HAVEN, Conn., Jan. 20, 2022 (GLOBE NEWSWIRE) -- (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its unaudited quarterly financia...
Bioasis Announces Annual General Meeting Results
Bioasis Announces Annual General Meeting Results NEW HAVEN, Conn., Dec. 16, 2021 (GLOBE NEWSWIRE) -- . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, is pleased to announce that all resolutions were passed by requisite majority at its annual general meeting (“AGM”) held earlier t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.